



2025

Discrepancies in Medical Information Responses from Pharmaceutical Companies Regarding Animal- Derived Ingredients

Introduction

Pharmaceutical companies often provide medical information regarding the presence of animal-derived ingredients in medications. However, inconsistencies and misleading responses can result in challenges for individuals with food allergies, Alpha-gal Syndrome (AGS), and dietary restrictions. This document highlights specific cases where discrepancies in information have been identified, demonstrating the need for greater transparency in pharmaceutical ingredient disclosure.

Why this Matters

Patients with dietary, religious, or medical restrictions rely on accurate ingredient information for safe medication use.

33M

people in the U.S.
have food allergies

500K

individuals are
affected by
Alpha-gal Syndrome
(AGS)

Key Findings

1

Contradictory Information from the Same Manufacturer

Example: A pharmaceutical company provided different ingredient disclosures in separate responses regarding the same product.

Case NUCALA: The manufacturer's response contained conflicting statements about the presence of animal-derived ingredients.

2

Misinformation in Med Info Responses vs. FDA DailyMed Database

Several manufacturers' responses contradicted publicly available ingredient data.

Example: Gabapentin – Manufacturer response stated no animal-derived ingredients, while the FDA DailyMed database indicated the presence of lactose.

3

Omissions of Key Ingredients

Some companies failed to disclose known animal-derived ingredients.

Example: Cephalexin – The response omitted gelatin despite its presence in the capsule formulation.

4

Risk to Alpha-gal Patients from Biologic Manufacturing Processes

Example: KEYTRUDA and STELARA – Produced in recombinant Chinese hamster ovary (CHO) cells, which could pose a risk for AGS patients, yet this was not explicitly disclosed by the manufacturer.

5

Delayed or Updated Information

Some manufacturers updated public ingredient listings only after inquiries were made.

Example: XELJANZ XR – The company revised its ingredient list following Pill Clarity's request for clarification.

Examples of Discrepancies

Medication	Reported Issue
Cephalexin	Gelatin omission in response letter
Gabapentin	Conflict between Med Info and FDA database
Avodart	Manufacturer denial of known lactose presence
Methylphenidate	No disclosure of potential shellac content
Promethazine	Missing details about animal-derived excipients
Prevident Toothpaste	Inconsistent responses on carrageenan presence
Keytruda/Stelara	No disclosure of CHO cell-derived formulation risk
Xeljanz XR	Updated ingredient listing only after inquiry
Tarpeyo	Inconsistent formulation details provided
Atorvastatin	Lack of transparency on inactive ingredients
Tramadol	Animal-derived components not explicitly disclosed
Azithromycin	Manufacturer uncertainty regarding shellac source
Morphine Sulfate	No confirmation of lactose presence

Call to Action

The inconsistencies highlighted in this document underscore the need for standardized, transparent ingredient disclosure in pharmaceutical products. Patients and healthcare professionals rely on accurate information to make informed decisions regarding medication safety. Pill Clarity Foundation calls on pharmaceutical companies to:

1	Develop standardized response letters regarding animal-derived ingredients.
2	Ensure consistency between internal Med Info responses and publicly available FDA DailyMed data.
3	Disseminate information via a central medical information platform like PillClarity.org.

Additional Reading Materials

1. Commins SP, Uchi J, Shah SA. Animal-derived ingredients in medicines: A call to action. DIA Global Forum. March 2024.
2. Gawel R. Alpha-gal in health products triggers anaphylaxis in half of alpha-gal syndrome patients. Healio. June 27, 2023.
3. Iglesia EGA, Kwan M, Virkud YV, et al. Management of food allergies and food-related anaphylaxis. JAMA. 2024;331(6):510–521.
4. Kinsella L, Brook J, Briest M, Brook MJ. Inconsistent excipient listings in DailyMed: Implications for drug safety. Naunyn Schmiedeberg's Arch Pharmacol. 2024;397(9):6851–6854.
5. Shek A, Watkins R, et al. Frequency of medication-related discussions within Alpha-Gal social media groups. Poster presentation at the American College of Cardiology Conference; April 2024.
6. Son F, Wolfe A, Uchi J, et al. Patient experience with pharmaceutical medical information centers to identify animal-free medications. J Contemp Pharm Pract. 2023;70(2a):8–11.
7. Tieu L, Uchi J, Nguyen Y, et al. Embracing medication needs of patients based on ethical, dietary, and religious preferences. Am J Lifestyle Med. 2022;18(3):351–363.
8. Uchi J, Commins SP, Wilson J, et al. Understanding health-related challenges in patients with Alpha-Gal Syndrome. Poster presentation at the DIA Global Annual Meeting; June 2023.
9. Venkat P, Nehrbas J, Figueroa E, Behm B, Wilson J. First-dose infusion reaction to ustekinumab is associated with the presence of serum IgE against galactose- α -1,3-galactose (α -gal). Am J Gastroenterol. 2024;119(12S):S11.
10. Wilson JM, Erickson L, Levin M, et al. Tick bites, IgE to galactose-alpha-1,3-galactose, and urticarial or anaphylactic reactions to mammalian meat: The Alpha-Gal Syndrome. Allergy. 2024;79:1440–1454.

About Pill Clarity Foundation

The Pill Clarity Foundation (PCF) is a nonprofit 501(c)(3) organization founded by Pill Clarity, a leader in medication safety and transparency. VMF promotes health by advocating for clear labeling of medication ingredients, catering specifically to individuals with dietary, ethical, and religious considerations.

Contact Information

www.pillclarityfoundation.org
info@pillclarity.org

References

1. Data and Research on File, Pill Clarity
2. J&J Medical Connect Ingredient Checker
3. FDA DailyMed Database
4. Pfizer Medical Information Ingredient and Allergen Checker

